UBS Group’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-119,798
| Closed | -$11.1M | – | 11503 |
|
|
2021
Q4 | $11.1M | Buy |
119,798
+63,121
| +111% | +$4.16M | ﹤0.01% | 2049 |
|
|
2021
Q3 | $3.38M | Buy |
56,677
+42,402
| +297% | +$2.5M | ﹤0.01% | 3107 |
|
|
2021
Q2 | $973K | Sell |
14,275
-40,157
| -74% | -$2.62M | ﹤0.01% | 4199 |
|
|
2021
Q1 | $3.78M | Buy |
54,432
+25,346
| +87% | +$1.95M | ﹤0.01% | 2909 |
|
|
2020
Q4 | $2.23M | Buy |
29,086
+11,667
| +67% | +$874K | ﹤0.01% | 3308 |
|
|
2020
Q3 | $1.3M | Buy |
17,419
+360
| +2% | +$24K | ﹤0.01% | 3449 |
|
|
2020
Q2 | $1.07M | Sell |
17,059
-19,123
| -53% | -$1.05M | ﹤0.01% | 3445 |
|
|
2020
Q1 | $1.52M | Buy |
36,182
+10,496
| +41% | +$481K | ﹤0.01% | 3018 |
|
|
2019
Q4 | $1.17M | Sell |
25,686
-45,621
| -64% | -$2.16M | ﹤0.01% | 4056 |
|
|
2019
Q3 | $3.26M | Buy |
71,307
+47,728
| +202% | +$2.68M | ﹤0.01% | 2798 |
|
|
2019
Q2 | $1.38M | Sell |
23,579
-1,219
| -5% | -$63K | ﹤0.01% | 3471 |
|
|
2019
Q1 | $1.11M | Sell |
24,798
-60,009
| -71% | -$2.75M | ﹤0.01% | 3496 |
|
|
2018
Q4 | $3.3M | Buy |
84,807
+28,444
| +50% | +$1.12M | ﹤0.01% | 2545 |
|
|
2018
Q3 | $2.59M | Buy |
56,363
+26,037
| +86% | +$1.06M | ﹤0.01% | 2988 |
|
|
2018
Q2 | $1.32M | Sell |
30,326
-102,921
| -77% | -$4.42M | ﹤0.01% | 3536 |
|
|
2018
Q1 | $5.26M | Buy |
133,247
+100,081
| +302% | +$3.89M | ﹤0.01% | 2260 |
|
|
2017
Q4 | $1.13M | Sell |
33,166
-7,740
| -19% | -$220K | ﹤0.01% | 3693 |
|
|
2017
Q3 | $1.04M | Buy |
40,906
+38,007
| +1,311% | +$872K | ﹤0.01% | 3675 |
|
|
2017
Q2 | $49K | Sell |
2,899
-311
| -10% | -$4.26K | ﹤0.01% | 5661 |
|
|
2017
Q1 | $47K | Sell |
3,210
-6,900
| -68% | -$102K | ﹤0.01% | 5574 |
|
|
2016
Q4 | $144K | Buy |
10,110
+3,483
| +53% | +$53.9K | ﹤0.01% | 5022 |
|
|
2016
Q3 | $116K | Buy |
6,627
+730
| +12% | +$12.1K | ﹤0.01% | 4910 |
|
|
2016
Q2 | $101K | Buy |
5,897
+374
| +7% | +$6.69K | ﹤0.01% | 5021 |
|
|
2016
Q1 | $109K | Sell |
5,523
-32,404
| -85% | -$519K | ﹤0.01% | 4911 |
|
|
2015
Q4 | $721K | Buy |
37,927
+33,554
| +767% | +$684K | ﹤0.01% | 3663 |
|
|
2015
Q3 | $84K | Buy |
4,373
+257
| +6% | +$8.73K | ﹤0.01% | 5374 |
|
|
2015
Q2 | $191K | Sell |
4,116
-3,486
| -46% | -$151K | ﹤0.01% | 4910 |
|
|
2015
Q1 | $332K | Buy |
7,602
+1,272
| +20% | +$59.1K | ﹤0.01% | 4473 |
|
|
2014
Q4 | $220K | Buy |
+6,330
| New | +$257K | ﹤0.01% | 4958 |
|
UBS Group's ARNA Position: Q1 2022 in Review
UBS Group sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 119,798 shares — an estimated $11.1M sold.
UBS Group first reported a position in ARNA in Q4 2014 and held it in 29 quarters. The position peaked at $11.1M in Q4 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- UBS Group reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- UBS Group sold 119,798 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $11.1M.
- UBS Group first reported a position in Arena Pharmaceuticals Inc in Q4 2014 and held it in 29 quarters.
- UBS Group's Arena Pharmaceuticals Inc position peaked at $11.1M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on UBS Group's 13F filing for Q1 2022, filed 16 May 2022.